About MBST UK

MBST UK brings together a network of independent clinics run by dedicated healthcare professionals from a variety of disciplines. Each shares a commitment to excellence, integrity, and innovation, delivering personalised care that supports recovery, promotes long-term health, and enhances quality of life.

Leading Team Members

Prof. Lord Kamlesh Patel

Chairman of the Board

Prof. Manahel Thabet

Chief Scientist

Dr. Charles Mamisch

Global Chief Executive Officer

Liz Clare

Managing Director

Charles Clare

Chief Technical Officer

Anna Schreiner a caucasian woman with long brown hair wearing a black shirt

Dr. Anna Schreiner

Chief Medical Officer

The MBST UK Clinical Network

Our clinical network connects MBST providers across the UK, bringing together healthcare professionals with a shared commitment to high standards of care. By working collaboratively, our clinics exchange knowledge, follow consistent protocols, and contribute to ongoing research and development. This collective approach ensures that every patient, wherever they are in the UK, receives the same quality experience and access to proven MBST technology.

Find your nearest clinic

Our Principles in Action

Our Vision

To use a variety of successful treatment methods and unique technology to deliver the highest level of care and treatment to as many patients as possible.

Our mission

To improve quality of life by providing exemplary patient care through a community of dedicated healthcare professionals. We combine successful treatment methods with proven MBST technology to address the source of the issue, not just the symptoms.

Our values

At MBST UK we treat with empathy, not ego, always doing what is best for each individual patient. What matters most is the patient outcome.

The Evolution of MBST – in a nutshell

An interesting discovery

Radiologists noticed that patients undergoing multiple MRI scans for joint or muscle issues sometimes reported unexpected improvements, such as less pain, easier movement, more energy, and better quality of life.

Investigation

A team of doctors, biologists, and physicists explored these findings further. They hypothesised that the effects might begin at a cellular level, possibly influenced by the resonance of water protons in tissues. This insight inspired the idea of creating a specialised, cost-effective MR-based technology for targeted therapy.

Turning discovery into technology

Research into how tissues respond to magnetic resonance led to the development of the first low-field MBST device. After three years of trials, it launched in Germany in 1998 with promising early results, prompting continued investigation and refinement.

Evidence builds

Laboratory studies have indicated that MBST may support normal cell activity without harming cells. Clinical data have shown that many patients report improvements in comfort and mobility following MBST therapy.

Reference: Temiz-Artman et al., “NMR in vitro effects on proliferation, apoptosis, and viability of human chondrocytes and osteoblasts.”

Wider potential

Subsequent studies suggest MBST may help support the body’s natural processes, potentially contributing to tissue stability, repair, and reduced inflammation, with possible benefits extending beyond musculoskeletal issues.

Proven results in osteoarthritis

A comprehensive review by Schmidt, Debess, and Møller (University College of Northern Denmark) reported significant improvements in pain and mobility in osteoarthritis patients. On average, pain levels were reduced by about half, even in advanced stages of the condition, with benefits lasting for up to a year.

Continuing progress

Research into MBST continues to advance, aiming to deepen understanding of its mechanisms and broaden its potential applications. New devices and protocols are regularly developed, guided by clinical experience, patient feedback, and ongoing scientific progress.